Photocure provides update on Karl Storz’s commitment to maximize the commercial adoption of Saphira™ and decision to discontinue flexible BLC tower production in the U.S.
Oslo, Norway, March 21, 2023 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces Karl Storz’s continued commitment to blue light cystoscopy with plans to maximize the ongoing rollout of its new high-definition rigid blue light cystoscopy (BLC[®]) system, Saphira™. Due to previously disclosed component supply issues Karl Storz has decided to discontinue production of flexible BLC equipment. Upon reclassification, Karl Storz will explore the development of a high-quality next generation flexible blue light system.Earlier today, Karl Storz informed Photocure that it will